Our goal is to catch pancreatic cancer before it becomes a late-stage diagnosis.
Pancreatic cancer accounts for only 3% of new cancer cases, yet it is the third leading cause of cancer death in the United States, underscoring the urgency for earlier detection when more effective therapies are still possible.
Bluestar Genomics’ first early cancer detection test is for pancreatic cancer, specifically for people over 50 recently diagnosed with Type 2 diabetes.
With multiple publications demonstrating the feasibility and validity of Bluestar Genomics’ test, the FDA granted it breakthrough device designation, supporting our novel approach to detecting the deadliest cancers.
With the prevalence of diabetes increasing worldwide, it is estimated that by 2025, more than 37 million patients will have been diagnosed with diabetes in the U.S. With such growing prevalence, it is imperative that we change the paradigm of late diagnosis depriving patients of effective treatments.